Solid Neoplasms Clinical Trial
Official title:
An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor
The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor type.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02896049 -
Celsius TCS Hyperthermia System PMCF Trial
|
||
Active, not recruiting |
NCT03833700 -
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
|
Phase 1 | |
Recruiting |
NCT04407676 -
Improving Informed Consent for Early Phase Anti-Cancer Trials
|
N/A | |
Recruiting |
NCT04420884 -
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03364049 -
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
|
Phase 1 | |
Completed |
NCT01543282 -
Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles
|
N/A |